Upregulation of a potential prognostic biomarker, miR-155, enhances cell proliferation in patients with oral squamous cell carcinoma.
OBJECTIVE
We sought to investigate the role and diagnostic value of microRNA 155 (miR-155) in OSCC patients.


METHODS
Using real-time quantitative polymerase chain reaction analysis, miR-155 expression levels were assessed in OSCC cell lines and a cancerous HB cell line. The correlation between miR-155 expression level and clinical parameters was analyzed in 46 patients with OSCC. In addition, the effects of miR-155 on OSCC cell proliferation were evaluated by modulating its expression using an miR-155 mimic and antisense miR-155.


RESULTS
Significant upregulation of miR-155 was found in OSCC cell lines and in tissues of patients with OSCC. The receiver operator characteristic analysis indicated fair-to-good predictability. Overexpression of miR-155 correlated with the histologic grade (P = .033), and the upregulation of miR-155 enhanced OSCC cell proliferation.


CONCLUSIONS
In OSSC, upregulation of miR-155 correlated with the histologic grade and can be used as a potential prognostic biomarker.
Central Laboratory of Stomatology, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China; State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Nanjing University Medical School, Nanjing, China.
Yan-Hong
YH
Ni
Central Laboratory of Stomatology, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China.
Xiao-Feng
XF
Huang
Department of Oral and Maxillofacial Surgery, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China.
Zhi-Yong
ZY
Wang
Central Laboratory of Stomatology, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China; Department of Oral and Maxillofacial Surgery, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China.
Wei
W
Han
Department of Oral and Maxillofacial Surgery, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China.
Run-Zhi
RZ
Deng
Department of Oral and Maxillofacial Surgery, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China.
Yong-Bin
YB
Mou
State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Nanjing University Medical School, Nanjing, China.
Liang
L
Ding
State Key Laboratory of Pharmaceutical Biotechnology, Division of Immunology, Nanjing University Medical School, Nanjing, China. Electronic address: yayihou@nju.edu.cn.
Ya-Yi
YY
Hou
Department of Oral and Maxillofacial Surgery, Institute and Hospital of Stomatology, Nanjing University Medical School, Nanjing Stomatological Hospital, Nanjing, China. Electronic address: qinganghu@hotmail.com.
Qin-Gang
QG
Hu
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism; D002294:Carcinoma, Squamous Cell / Q000378:metabolism* / Q000473:pathology; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D008297:Male; D035683:MicroRNAs / Q000378:metabolism*; D008875:Middle Aged; D009062:Mouth Neoplasms / Q000378:metabolism* / Q000473:pathology; D060787:Neoplasm Grading; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D060888:Real-Time Polymerase Chain Reaction; D014407:Tumor Cells, Cultured; D015854:Up-Regulation
D014408:Biomarkers, Tumor; C524942:MIRN155 microRNA, human; D035683:MicroRNAs